LENSAR, Inc. (LNSR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

LENSAR, Inc. (LNSR) Healthcare & Pipeline Overview

LENSAR, Inc. develops and markets femtosecond laser systems for cataract and astigmatism treatment, leveraging proprietary imaging and planning technologies. The company aims to enhance surgical precision and visual outcomes in the medical device sector, operating within the broader healthcare industry.

What Is the Investment Thesis for LNSR?

LENSAR, Inc. presents a focused investment opportunity within the medical device sector, driven by its proprietary femtosecond laser technology for cataract and astigmatism treatment. With a market capitalization of $104M and a P/E ratio of 2.3, LENSAR shows potential for growth, supported by a strong profit margin of 50.9%. The company's growth catalysts include expanding its installed base of LENSAR Laser Systems and increasing utilization rates among existing customers. Key value drivers include the company's ability to innovate and develop new applications for its laser technology, as well as its potential to expand into new geographic markets. However, potential risks include competition from established players in the ophthalmic surgical device market and the need for ongoing investment in research and development to maintain its technological edge. The company's beta of 0.98 suggests moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

LNSR Key Highlights

Market capitalization of $104M indicates the company's current valuation in the market.

• P/E ratio of 2.3 suggests the stock may be undervalued compared to its earnings.
• Profit margin of 50.9% demonstrates strong profitability and efficient operations.
• Gross margin of 45.3% reflects the company's ability to control production costs and maintain pricing power.
• Beta of 0.98 indicates the stock's volatility is similar to the overall market.

Who Are LNSR's Competitors?

LNSR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LNSR's Key Strengths?

Proprietary femtosecond laser technology.

• Strong profit margin of 50.9%.
• Established presence in the ophthalmic surgical device market.
• Advanced imaging and procedure planning capabilities.

What Are LNSR's Weaknesses?

Relatively small market capitalization of $104M.

• Limited geographic reach compared to larger competitors.
• Dependence on a single product line (LENSAR Laser System).
• Requires ongoing investment in research and development.

What Could Drive LNSR Stock Higher?

LNSR catalyst: Continued expansion of the installed base of LENSAR Laser Systems in ophthalmic clinics and hospitals.

• Increasing utilization rates among existing customers through enhanced training and support programs.
• Potential regulatory approvals for new applications of the LENSAR Laser System in additional ophthalmic procedures.
• Strategic partnerships with key opinion leaders and influential surgeons to promote the adoption of LENSAR technology.
• Ongoing research and development efforts to enhance the capabilities and features of the LENSAR Laser System.

What Are the Key Risks for LNSR?

Financial-distress signal — its Altman Z-Score of 1.26 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Competition from established players in the ophthalmic surgical device market, such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb.
• Technological advancements by competitors that could render the LENSAR Laser System obsolete.
• Regulatory changes and healthcare reforms that could impact the adoption and reimbursement of cataract surgery procedures.
• Economic downturns that could affect healthcare spending and reduce demand for elective surgical procedures.
• Dependence on a single product line (LENSAR Laser System) makes the company vulnerable to market shifts and technological disruptions.

What Are the Growth Opportunities for LNSR?

• Expansion into international markets represents a significant growth opportunity for LENSAR. The global market for cataract surgery devices is expected to grow, driven by the increasing prevalence of cataracts in aging populations worldwide. By expanding its sales and marketing efforts into new geographic regions, LENSAR can tap into this growing demand and increase its revenue. The timeline for this expansion will depend on regulatory approvals and market entry strategies, but it represents a long-term growth driver for the company. Successfully entering new markets could significantly increase LENSAR's market share and revenue.
• Increasing the utilization rate of existing LENSAR Laser Systems is another key growth opportunity. LENSAR can work with its existing customers to provide additional training and support, helping them to perform more procedures using the LENSAR system. This would not only increase revenue from single-use procedure packs but also strengthen customer relationships and loyalty. The timeline for this growth opportunity is relatively short-term, as it can be achieved through targeted sales and marketing efforts. By focusing on customer satisfaction and providing ongoing support, LENSAR can drive increased utilization and revenue growth.
• Developing new applications for the LENSAR Laser System beyond cataract surgery and astigmatism management could open up new markets and revenue streams. For example, LENSAR could explore the use of its laser technology for other ophthalmic procedures, such as corneal refractive surgery or glaucoma treatment. This would require further research and development, but it could significantly expand the company's addressable market. The timeline for this growth opportunity is longer-term, as it will depend on the success of research and development efforts and regulatory approvals. However, it represents a significant potential growth driver for the company.
• Strategic partnerships with ophthalmic surgeons and clinics can help LENSAR to increase its market reach and brand awareness. By collaborating with key opinion leaders and influential surgeons, LENSAR can gain valuable insights into market trends and customer needs. These partnerships can also help to promote the LENSAR Laser System and increase its adoption among surgeons. The timeline for this growth opportunity is ongoing, as LENSAR can continuously seek out new partnerships and collaborations. By building strong relationships with key stakeholders in the ophthalmic community, LENSAR can strengthen its competitive position and drive growth.
• Investing in research and development to enhance the capabilities of the LENSAR Laser System is essential for maintaining a competitive edge. By continuously innovating and developing new features and applications for its technology, LENSAR can attract new customers and retain existing ones. This includes improving the precision and accuracy of the laser system, as well as developing new software and imaging capabilities. The timeline for this growth opportunity is ongoing, as LENSAR must continuously invest in research and development to stay ahead of the competition. By maintaining a focus on innovation, LENSAR can drive long-term growth and create value for its shareholders.

What Are LNSR's Competitive Advantages?

• Proprietary femtosecond laser technology with advanced imaging and planning capabilities.
• Established installed base of LENSAR Laser Systems in ophthalmic clinics and hospitals.
• Strong relationships with ophthalmic surgeons and key opinion leaders.
• Ongoing investment in research and development to maintain technological edge.

What Does LNSR Do?

LENSAR, Inc., established in 2004 and headquartered in Orlando, Florida, is a commercial-stage medical device company focused on advancing cataract surgery and astigmatism management through innovative laser technology. The company designs, develops, and markets the LENSAR Laser System, a femtosecond laser platform that incorporates proprietary technologies aimed at improving surgical precision, efficiency, and patient outcomes. The LENSAR system provides surgeons with advanced imaging, procedure planning, and design capabilities to assist in cataract removal and the correction of pre-existing or surgically induced corneal astigmatism. The LENSAR Laser System's key features include its advanced 3D modeling and precise laser delivery, which allow surgeons to create customized treatment plans tailored to each patient's unique anatomy. This technology aims to enhance the accuracy and reproducibility of cataract surgery, potentially leading to better visual outcomes and reduced complications. LENSAR's focus on innovation and technological advancement positions it as a player in the ophthalmic surgical device market, serving ophthalmologists and surgeons seeking to improve their surgical techniques and patient care. LENSAR's business model involves the sale and service of its LENSAR Laser Systems, as well as the sale of single-use procedure packs. The company's revenue is derived from these sources, as well as from service contracts and training programs for surgeons and staff. LENSAR's commitment to ongoing research and development ensures that its technology remains at the forefront of the ophthalmic surgical field.

What Products and Services Does LNSR Offer?

• Designs and develops femtosecond laser systems for cataract surgery.
• Markets the LENSAR Laser System to ophthalmic surgeons and clinics.
• Provides advanced imaging and procedure planning capabilities.
• Offers solutions for managing pre-existing or surgically induced astigmatism.
• Enhances surgical precision and reproducibility in cataract treatment.
• Provides training and support to surgeons using the LENSAR system.
• Sells single-use procedure packs for use with the LENSAR Laser System.

How Does LNSR Make Money?

• Sales of LENSAR Laser Systems to ophthalmic surgeons and clinics.
• Recurring revenue from the sale of single-use procedure packs.
• Service contracts and maintenance agreements for the LENSAR Laser Systems.
• Training programs and support services for surgeons and staff.

What Industry Does LNSR Operate In?

LENSAR, Inc. operates within the medical device industry, specifically focusing on ophthalmic surgical devices. The market for cataract surgery devices is driven by the aging global population and the increasing prevalence of cataracts. The competitive landscape includes established players such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb, as well as other smaller companies offering femtosecond laser systems. LENSAR differentiates itself through its proprietary technology and focus on precision and customization in cataract and astigmatism treatment. The industry is characterized by ongoing innovation and technological advancements, with companies constantly seeking to improve surgical outcomes and patient satisfaction.

Who Are LNSR's Key Customers?

• Ophthalmic surgeons specializing in cataract surgery.
• Ophthalmology clinics and hospitals offering cataract treatment.
• Patients seeking advanced cataract surgery options.
• Healthcare providers focused on improving surgical outcomes and patient satisfaction.

LENSAR, Inc. (LNSR) Valuation Context

Valued at $104M, LNSR is classified as a micro-cap stock. Relative to its peer group, LNSR's quantitative score of 43/100 is below the peer average of 64/100.

LNSR Revenue & Earnings Trend

In Q2 2026, LNSR generated $16.5M in top-line revenue, marking a sequential increase of 22.8%. The company recorded net income of $3.5M, with diluted EPS of $0.10. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, LNSR averaged $-0.08 in diluted EPS.

Company Profile

LENSAR, Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Nicholas T. Curtis. LNSR has traded publicly since 2020.

Return on assets is 44.4%, showing how much profit it generates from its asset base. LNSR trades at a trailing price-to-earnings ratio of 2.35, below the Healthcare sector average of ~23x. Its free cash flow yield is -17.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 42.0%, the inverse of the P/E and a quick read on earnings relative to price.

LENSAR, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.26 places it in the distress zone, a signal of elevated financial risk.

LENSAR, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 207.5% below estimates on average.

Wall Street analysts project LENSAR, Inc. revenue of about $61.3M for fiscal 2026, with EPS near $0.97.

LNSR Financials

LNSR Latest News

LNSR Analyst Consensus

LNSR MoonshotScore

What Investors Ask About LENSAR, Inc. (LNSR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources